- Trials with a EudraCT protocol (244)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
244 result(s) found for: Chronic active hepatitis.
Displaying page 1 of 13.
EudraCT Number: 2012-002069-36 | Sponsor Protocol Number: 5189 | Start Date*: 2013-02-06 | |||||||||||
Sponsor Name:Hôpitaux Universitaires de Strasbourg | |||||||||||||
Full Title: Randomized controlled clinical trial investigating Erlotinib for the treatment of chronic hepatitis C virus infection | |||||||||||||
Medical condition: C hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001071-40 | Sponsor Protocol Number: ISM10-06 | Start Date*: 2011-08-11 | ||||||||||||||||
Sponsor Name:InSpira Medical AB | ||||||||||||||||||
Full Title: A Phase IIa Safety study of oral administration of anti-CD3 monoclonal antibody in non-responder genotype-I chronic Hepatitis C subjects, a single-blind, randomized, controlled multi-center study | ||||||||||||||||||
Medical condition: in non-responder genotype-I chronic Hepatitis C subjects | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) PL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003853-29 | Sponsor Protocol Number: METVIRAL | Start Date*: 2005-12-09 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: A randomized, controlled, multicenter clinical trial comparing the efficacy of Peginterferon alfa-2a and ribavirin and metformin versus Peginterferon alfa-2a and ribavirin for the treatment of naïv... | |||||||||||||
Medical condition: CHRONIC ACTIVE HEPATITIS C ASSOCIATED WITH INSULIN RESISTANCE | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001024-21 | Sponsor Protocol Number: nc5317 | Start Date*: 2018-02-23 | ||||||||||||||||
Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli" | ||||||||||||||||||
Full Title: innovative model for the eradication of HCV in a population at high risk of irregular immigrants and low-income refugees | ||||||||||||||||||
Medical condition: Chronic HCV hepatitis, all fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003136-22 | Sponsor Protocol Number: GS-US-174-0106 | Start Date*: 2006-05-05 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combina... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015002-19 | Sponsor Protocol Number: VTI-206 | Start Date*: 2010-01-18 | |||||||||||
Sponsor Name:VITAL THERAPIES INCORPORATED | |||||||||||||
Full Title: EFFICACY AND SAFETY OF ELAD IN SUBJECTS WITH ACUTE ON CHRONIC HEPATITIS (AOCH) | |||||||||||||
Medical condition: Acute on Chronic Hepatitis (AOCH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004138-41 | Sponsor Protocol Number: TEL-PR | Start Date*: 2012-12-10 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PARMA | |||||||||||||
Full Title: Anti-viral T cell responses in patients with chronic HCV infection treated with telaprevir: can therapy induce functional T cell reconstitution? | |||||||||||||
Medical condition: Chronic active hepatitis C never treated previously with anti-HCV therapies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002911-27 | Sponsor Protocol Number: BOC-PR | Start Date*: 2011-09-30 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PARMA | |||||||||||||
Full Title: Effect of boceprevir therapy on HCV-specific T cell responses: perspectives of immune monitoring and immune therapy | |||||||||||||
Medical condition: Chronic active hepatitis C never treated previously with anti-viral terapie | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001884-21 | Sponsor Protocol Number: VTI-210 | Start Date*: 2013-07-26 | |||||||||||
Sponsor Name:VITAL THERAPIES INCORPORATED | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH SEVERE ACUTE ALCOHOLIC HEPATITIS (SAAH) AND LILLE SCORE FAILURE | |||||||||||||
Medical condition: Severe Acute Alcoholic Hepatitis (sAAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002641-11 | Sponsor Protocol Number: GS-US-334-0153 | Start Date*: 2013-10-07 | ||||||||||||||||
Sponsor Name:Gilead Sciences Inc. | ||||||||||||||||||
Full Title: A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 ... | ||||||||||||||||||
Medical condition: Hepatitis C Virus Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003446-27 | Sponsor Protocol Number: TMC435HPC3021 | Start Date*: 2015-01-02 | |||||||||||
Sponsor Name:Janssen R&D Ireland | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve or -Experienced Subj... | |||||||||||||
Medical condition: Hepatitis C-Infection genotype 4 Patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004212-64 | Sponsor Protocol Number: IMC-I109V-101 | Start Date*: 2020-08-12 | ||||||||||||||||
Sponsor Name:Immunocore Ltd | ||||||||||||||||||
Full Title: An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Patients with Chronic HBV who are Non-Cirrhotic, Hepatitis B e Antigen-nega... | ||||||||||||||||||
Medical condition: chronic hepatitis B virus (HBV) infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) PL (Prematurely Ended) RO (Completed) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002008-28 | Sponsor Protocol Number: 2017-002008-28 | Start Date*: 2017-12-21 | |||||||||||
Sponsor Name:Region Skåne | |||||||||||||
Full Title: A prospective open label study to evaluate treatment of chronic HCV infection with glecaprevir/pibrentasvir in PWID attending a needle exchange program | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006803-35 | Sponsor Protocol Number: CABF656A2201 | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... | |||||||||||||
Medical condition: CHONIC HEPATITIS C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020033-14 | Sponsor Protocol Number: CDEB025A2210 | Start Date*: 2010-09-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicentre, randomized, double-blind, placebocontrolled, parallel-group phase II study on efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genotyp... | |||||||||||||
Medical condition: Chronic Hepatitis C Genotype 1 patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) DE (Completed) FR (Completed) ES (Completed) BE (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003704-35 | Sponsor Protocol Number: GS-US-174-0115 | Start Date*: 2008-12-11 | |||||||||||
Sponsor Name:Gilead Science Incorporated | |||||||||||||
Full Title: A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection | |||||||||||||
Medical condition: Chronic hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FR (Completed) ES (Completed) BG (Completed) DE (Completed) GR (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002920-14 | Sponsor Protocol Number: VX-950-TiDP24-C209 | Start Date*: 2007-11-14 | |||||||||||
Sponsor Name:Tibotec BVBA | |||||||||||||
Full Title: A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection | |||||||||||||
Medical condition: Hepatitis C infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004751-31 | Sponsor Protocol Number: Heparc-2003 | Start Date*: 2015-06-26 | |||||||||||
Sponsor Name:Arrowhead Research Corporation | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination wi... | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023669-23 | Sponsor Protocol Number: VX-950HEP3002 | Start Date*: 2011-04-06 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirr... | |||||||||||||
Medical condition: Chronic hepatitis C infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed) HU (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003990-23 | Sponsor Protocol Number: BP42698 | Start Date*: 2021-06-21 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWING STEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS | |||||||||||||
Medical condition: Autoimmune Hepatitis (AIH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Completed) PT (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
